logo
The future of transit isn't flashy, it's functional

The future of transit isn't flashy, it's functional

Fast Company11-07-2025
When it comes to the future of urban mobility, it's not the sci-fi fantasies that will shape our cities. It's functional solutions for the everyday. While tech visionaries promote high-speed concepts like ET3's vacuum-sealed capsules, true transformation will come from transportation solutions that are accessible, reliable, and affordable—like modernizing existing transit infrastructure, digitizing bus routes, and reducing traffic congestion. Sexy, futuristic modes of transportation like autonomous vehicles may dominate the headlines, but what Americans really crave are reliable, inexpensive options to get them from point A to point B—not a self-driving car.
Public frustration around the future of transit is mounting. Waymos are crashing in Los Angeles, congestion pricing is contentious in New York City, and the U.S. lacks a reliable high-speed rail network. These realities make it clear that companies should rethink what the 'city of the future' looks like and reprioritize achievable solutions to real needs.
New data from Censuswide, commissioned by Diffusion, offers a closer look at the evolving sentiment on mobility in America's biggest cities—and the findings highlight a pressing need for better solutions. Alarmingly, fewer than 18% of Americans describe their city's transit as 'highly efficient' and nearly as many say it's 'struggling.' With American people driving around twice as much annually compared to their European counterparts, the overreliance on personal vehicles underscores the urgency for investments in reliable public transit that can reduce congestion, cut emissions and improve quality of life.
While exciting, the novelty of new mobility tech, like the 2,000 new food delivery bots roaming around Los Angeles, wears off quickly when residents can depend more on their takeout delivery than the bus they take to work. In fact, bus delays are collectively costing L.A. residents more than a cumulative decade on the average weekday. Despite the ability to ask ChatGPT nearly any question and get the answer in seconds, Americans are understandably frustrated that they can't seem to get an accurate transit schedule.
Back to the basics
The top three priorities for Americans when it comes to urban mobility are affordability (50.8%), reliable public transit (47%), and accessibility (39.3%)— demonstrating a need for options that reduce traffic congestion, provide economical alternatives, and are available to all. Visionaries in the urban mobility space need to focus on these core components before setting their sights on mass adoption. Without demonstrating a positive potential impact on cost, convenience, reliability, and ease of use, companies innovating in the space will only continue to be met with skepticism and resistance.
Fears around AV
Sentiment around automated vehicles (AVs), for example, perfectly illustrates the increasing skepticism and resistance to adapt. Despite AVs being at the forefront of the future and modern urban transit conversation, the public isn't on board, with over half (50.5%) of respondents disagreeing that AV's are the 'future.'
Furthermore, 74.5% of Americans said they don't trust the safety of AVs and 66% said that the technology isn't ready. Yet just this month, Waymo announced they are expanding to New York City. This move suggests that companies in the urban mobility space may be out of touch with what American commuters are ready to embrace. AVs still don't feel normal or comfortable to most, so now is the time to build trust. Rolling them out at scale without addressing fundamental mobility concerns risks missing the mark entirely, since commuters need confidence in the safety and reliability of the technology before they'll consider taking the risk themselves.
Beyond issues of trust and comfort, however, concerns extend to the broader economic impact of AVs. Nearly 60% said they're concerned about AVs impact on jobs, a sentiment that isn't surprising given growing fears about AI 's effects on the American workforce and the disappearance of certain roles. While businesses race to advance AV technology, assuming widespread excitement for futuristic transportation options, they often overlook how these developments will directly affect everyday people.
Job loss is not the only aspect of new technology that concerns Americans—privacy remains at the forefront of conversation, with over 60% of people reporting a concern for their digital safety. Many of these 'futuristic' transport options require a certain amount of data about oneself, location, etc. which can be scary to the everyday commuter. Companies modernizing urban mobility should focus on transparency when it comes to data collection, to help ease user's minds, and highlight the ways in which their technology will tangibly improve day-to-day lives. Otherwise, they'll face resistance in the pursuit of mass acceptance.
The real 'City of the Future'
Since what Americans truly want isn't flying cars or futuristic cities, efforts should focus on enhancing existing infrastructure through smart technology instead of pursuing a complete overhaul. Innovations that fail to get someone to their destination quickly and affordably are far less 'transformative' than companies believe.
The real future of urban mobility isn't about who has the flashiest new system, it's about who solves the real problems. 'Progress' is about improving upon how people live, work and move within cities, not making headlines for futuristic features that don't have real-world impact. Before we prioritize the 'city of the future,' let's strengthen our cities in the present.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Yahoo

time26 minutes ago

  • Yahoo

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) ('Sana'), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC, and Sana will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering, copies of which can be accessed for free through the SEC's website at When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@ Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction. About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the completion, timing, and size of the proposed offering and our intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not we will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the proposed public offering. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations & Media: Nicole in to access your portfolio

Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025
Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025

Yahoo

time26 minutes ago

  • Yahoo

Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025

Live Conference Call and Webcast Scheduled to Begin at 8:30 a.m. ET on August 12, 2025 NEWTON, Mass., August 06, 2025--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT) ("Informa TechTarget" or the "Company"), a leading growth accelerator for the B2B Technology sector, today announced that it will release its Q2 2025 financial results for the three months ended June 30, 2025 before the market opens on Tuesday, August 12, 2025. The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 8:30 a.m. Eastern Time on that day to discuss the Company's financial results and outlook. The Q2 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at Conference Call Dial-In Information: United States (Toll Free): 1-833-470-1428 United States: 1-404-975-4839 United Kingdom (Toll Free): +44 808 189 6484 United Kingdom: +44 20 8068 2558 Global Dial-in Numbers Access code: 967110 Please access the call at least 10 minutes prior to the time the conference is set to begin. Please ask to be joined into the Informa TechTarget call. Conference Call Webcast Information: This webcast can be accessed via Informa TechTarget's website at Conference Call Replay Information: A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through September 11, 2025 at 11:59 p.m. ET. To hear the replay: United States (Toll Free): 1-866-813-9403 United States: 1-929-458-6194 Access Code: 703085 A web version will also be available for replay during the same period on Informa TechTarget's website at About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Investor Inquiries Daniel NoreckMitesh KotechaInforma TechTarget617-431-9200investor@ Media Inquiries Garrett MannCorporate CommunicationsInforma

Corteva raises annual profit forecast after strong first-half performance
Corteva raises annual profit forecast after strong first-half performance

Yahoo

time26 minutes ago

  • Yahoo

Corteva raises annual profit forecast after strong first-half performance

(Reuters) -U.S. agrichemicals company Corteva raised its annual adjusted profit forecast on Wednesday, following strong performance in the first half of the year. Reuters had reported in May that U.S. farmers have hit very few snags with corn planting this spring, and the foreseeable future is barrier-free. Corteva's net sales rose 5.6% to $6.46 billion during the second quarter, driven by higher sales in all its regions. The company is among the largest crop-protection product makers in the United States, competing with the likes of Syngenta and German firms BASF and Bayer in the agricultural chemicals sector. The company raised its forecast for full-year adjusted earnings to be between $3.00 to $3.20 per share, from a prior view of $2.70 to $2.95 per share.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store